采用单参数MRI联合前列腺特异性抗原检测临床显著性前列腺癌的理由:与标准双参数及多参数MRI的比较
本研究纳入193例患者,比较仅用弥散加权成像的单参数MRI与双参数及多参数MRI检测临床显著性前列腺癌(CSC)的效能,并评估单参数MRI结果联合PSA水平的效果。单参数MRI诊断效能与双参数及多参数MRI相似,在单参数MRI阴性患者中应用新的PSA截断值可提高敏感度。
要点
- 单参数MRI(仅DWI)检测CSC的效能与双参数及多参数MRI无显著差异。
- 单参数MRI的读者间一致性ICC=0.798,与双参数(0.751)及多参数(0.714)相当。
- 单参数MRI阴性者联合新PSA截断值可提高敏感度,减少漏诊。
核心结论
- 仅基于DWI的单参数MRI在检测CSC方面表现出与双参数及多参数MRI相似的诊断效能,且PSA水平联合单参数MRI有潜力有效分诊高 likelihood 的CSC患者。
研究设计与样本
- 本研究为回顾性研究,纳入193例患者(平均年龄70.5岁,平均PSA 7.9 ng/mL),于2020年1月至2022年2月接受活检前MRI及随后的前列腺活检;两名放射科医生独立使用PI-RADS对三种MRI方案进行评分,采用组内相关系数(ICC)评估读者间一致性,采用受试者工作特征(ROC)曲线分析评估诊断效能,采用约登指数确定单参数MRI阴性患者中检测CSC的新PSA截断值。
诊断标准与关键数值
- CSC confirmed in 109 patients (56.5%);单参数MRI读者间一致性ICC=0.798,双参数MRI ICC=0.751,多参数MRI ICC=0.714;三种方案检测CSC的ROC曲线分析无差异(P > 0.05);在单参数MRI阴性患者中应用新PSA截断值(分别为9.5和7.4 ng/mL)后,读者1的敏感度从89.9%提高至96.3%,读者2的敏感度从95.4%提高至99.1%。
临床应用与阅片要点
- 单参数MRI(仅DWI)可作为检测临床显著性前列腺癌的选项,其诊断效能与双参数及多参数MRI相似;对于单参数MRI阴性的患者,结合新的PSA截断值(读者1为9.5 ng/mL,读者2为7.4 ng/mL)可提高敏感度,可能减少漏诊前列腺癌。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare prostate monoparametric MRI (monoMRI), which uses only diffusion-weighted imaging (DWI), with biparametric (bpMRI) and multiparametric MRI (mpMRI) in detecting clinically significant cancer (CSC) and to evaluate the effect of the combination of monoMRI results and prostate-specific antigen (PSA) level.
METHODS: In this study, 193 patients (average age 70.5 years; average PSA 7.9 ng/mL) underwent prebiopsy MRI and subsequent prostate biopsy from January 2020 to February 2022. Two radiologists independently reviewed the 3 MRI protocols using the Prostate Imaging Reporting and Data System (PI-RADS). Interreader agreement was assessed using the intraclass correlation coefficient (ICC), and diagnostic performance was evaluated with receiver operating characteristic (ROC) curve analysis. The Youden index was used to determine the new cutoff value of PSA for detecting CSCs in patients with negative monoMRI results.
RESULTS: CSC was confirmed in 109 patients (56.5%). The interreader agreement on monoMRI (ICC = 0.798) was comparable to that on bpMRI and mpMRI (ICC = 0.751 and 0.714, respectively). ROC curve analysis of the 3 protocols revealed no difference in detecting CSCs (P > 0.05). Applying a new PSA cutoff value (9.5 and 7.4 ng/mL, respectively) in monoMRI-negative patients improved the sensitivity of monoMRI from 89.9% to 96.3% for Reader 1, and from 95.4% to 99.1% for Reader 2.
CONCLUSIONS: MonoMRI based solely on DWI demonstrated similar diagnostic performance to bpMRI and mpMRI in detecting CSCs, and the combination of PSA level with monoMRI has the potential to effectively triage patients with a high likelihood of CSCs.
ADVANCES IN KNOWLEDGE: Monoparametric MRI conducted only with diffusion-weighted imaging (DWI), may show comparable performance to biparametric and multiparametric MRI in detecting clinically significant prostate cancer. In patients with negative monoparametric MRI results, implementing a new PSA cutoff value to determine the need for a biopsy could decrease the number of missed prostate cancer.
引用
- Park SH, Choi MH, Lee YJ, et al. Rationale for adopting a combination of monoparametric MRI with the prostate-specific antigen in detecting clinically significant prostate cancer: comparison with standard biparametric and multiparametric MRI. Br J Radiol. 2024. PMID: 39212614. doi:10.1093/bjr/tqae134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。